US 2026/0226141 A1 · ANTIBODIES AGAINST MULTIDRUG-RESISTANT KLEBSIELLA PNEUMONIAE

Abstract

The present invention relates to monoclonal antibodies or antigen-binding portion thereof that have a potent antibacterial activity against Klebsiella pneumoniae, in particular against multi-drug resistant Klebsiella pneumoniae strains. The invention relates also to the use of such monoclonal antibodies or antigen-binding portion thereof in therapy, prophylaxis, and diagnosis of Klebsiella pneumoniae infections, in particular Klebsiella pneumoniae dependent diseases.

Claims21

Dependent claims

A human monoclonal antibody or an antigen-binding portion thereof that specifically binds to a surface antigen of Klebsiellapneumoniae.

Dependencies are inferred from the claim text.

Facts

Application

19/150,284Filed 19 Jan 2024

Priority

IT 10202300000092423 Jan 2023

Published

6 Aug 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07K 16/1228
Gram-negative bacteria: enterobacterales , e.g. Citrobacter , Serratia , Proteus , Providencia , Morganella or Yersinia
A61P 31/04
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
C07K 16/06
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: from serum

Antibodies against multidrug-resistant klebsiella pneumoniae

Life of this patent

Antibodies against multidrug-resistant klebsiella pneumoniae

Life of this patent

Abstract

Claims21